Agenus Partners with Tanner Pharma to Improve Access to Innovative Cancer Therapies

A New Era in Cancer Care: Agenus and Tanner Pharma Join Forces

Agenus, an innovator in immuno-oncology, collaborates with Tanner Pharma to enhance patient access to investigational therapies botensilimab (BOT) and balstilimab (BAL). This partnership introduces a Named Patient Program (NPP) aimed at individuals suffering from microsatellite stable colorectal cancer (MSS CRC) and other advanced solid tumors. The NPP allows eligible patients to receive these treatments based on clinical evidence and medical necessity, even before formal regulatory approval. Tanner Pharma is responsible for managing patient access in regions that permit such initiatives, ensuring compliance with ethical and regulatory standards.

The significance of this collaboration lies in the potential of BOT and BAL to redefine treatment protocols for challenging cancers. Both therapies show promise in treating historically resistant tumors, with clinical trials reporting complete pathological responses in neoadjuvant MSS colon cancer patients. Furthermore, durable tumor responses have been observed across various cancer types, suggesting that these immunotherapies could become essential components of future cancer treatment strategies. By facilitating access to these investigational therapies, the NPP addresses the urgent need for effective options for patients with severe health challenges.

Founded in 1994 and headquartered in Lexington, Massachusetts, Agenus is committed to advancing cancer immunotherapy. The company has developed a diverse portfolio of immunological agents, including antibody therapeutics and cell therapies. Tanner Pharma specializes in global access solutions for specialty medications, focusing on connecting patients and healthcare providers through compassionate use and expanded access programs. This collaboration not only reflects a growing trend in the pharmaceutical industry to provide early access to potentially life-saving therapies but also emphasizes the importance of patient safety and ethical considerations in drug accessibility.

In addition to facilitating access through the NPP, both Agenus and Tanner Pharma encourage interested individuals to explore clinical trials for botensilimab. Relevant information can be found at clinicaltrials.gov under multiple identifiers. This initiative is a crucial step toward improving treatment options for patients facing complex cancer cases, providing hope and potential new avenues for care.